HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Zanamivir (Relenza)

A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.

Also Known As:

Relenza; 2,3-Didehydro-2,4-Dideoxy-4-Guanidino-N-Acetyl-D-Neuraminic Acid; 2,3-Didehydro-2,4-Dideoxy-4-Guanidinyl-N-Acetylneuraminic Acid; 4-Guanidino-2,4-Dideoxy-2,3-Didehydro-N-Acetylneuraminic Acid; 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic Acid; 4-Guanidino-Neu5Ac2en; 5-Acetylamino-2,6-Anhydro-4-Guanidino-3,4,5-Trideoxy-D-Galacto-Non-Enoic Acid; Biota Brand of Zanamivir; GG 167; GG-167; GG167; Glaxo Wellcome Brand of Zanamivir; GlaxoSmithKline Brand of Zanamivir; 4 Guanidino 2 Deoxy 2,3 Didehydro N Acetylneuraminic Acid; 4 Guanidino Neu5Ac2en; Acid, 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic; Zanamivir Biota Brand; Zanamivir GlaxoSmithKline Brand; 5-acetylamino-4-guanidino-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid

Networked: 567 relevant articles (101 outcomes, 106 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Hurt, Aeron C: 13 articles (11/2015 - 01/2003)
2.	McKimm-Breschkin, Jennifer L: 11 articles (02/2015 - 02/2002)
3.	Ikematsu, Hideyuki: 11 articles (01/2015 - 06/2007)
4.	Gubareva, Larisa V: 10 articles (10/2015 - 03/2008)
5.	Kashiwagi, Seizaburo: 10 articles (01/2015 - 06/2007)
6.	Kawai, Naoki: 10 articles (01/2015 - 06/2007)
7.	Yamashita, Makoto: 9 articles (03/2010 - 08/2002)
8.	Boivin, Guy: 8 articles (12/2015 - 06/2002)
9.	Barr, Ian G: 8 articles (11/2015 - 01/2003)
10.	Iwaki, Norio: 8 articles (01/2015 - 06/2007)

Related Diseases

1.	Human Influenza (Influenza) 11/01/2005 - "The protective efficacy of zanamivir versus placebo for SLCI was marginal, for all laboratory confirmed illnesses, but significant against culture proven and febrile influenza, suggesting zanamivir can be effective for outbreak control and symptom reduction of unvaccinated institutionalized residents. " 12/01/2001 - "(3) Zanamivir has no proven efficacy in preventing the spread of influenza by a treated patient. " 08/01/2007 - "Previous studies conducted primarily in non-high-risk subjects have reported the efficacy of inhaled zanamivir in preventing influenza. " 11/01/2002 - "Clinical trials of zanamivir have reported a reduced incidence of influenza complications among high-risk patients. " 08/01/2007 - "Significantly fewer zanamivir-treated subjects developed symptomatic, laboratory- confirmed influenza during prophylaxis compared with placebo recipients (4/1678 vs 23/1685, respectively), representing a relative risk (RR) of 0.17 (95% CI, 0.07-0.44; P < 0.001) and a protective efficacy of 83%. "
2.	Infection 01/01/2010 - "He did well with complete clearance of the infection from the BAL after 10 days of Zanamivir, although the nasopharyngeal swabs remained positive for ten more days. " 09/01/2010 - "Compassionate use of intravenous zanamivir for the treatment of seriously ill patients, including those with H275Y H1N1 infections, has also shown promising results. " 09/01/1999 - "Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment." 12/01/2012 - "Efficient control of pandemic 2009 H1N1 virus infection with intravenous zanamivir despite the lack of immune function." 01/01/2012 - "Using in vitro models of infection, we aimed to clarify the effects of bacterial neuraminidases on influenza virus infection in the presence of the NA inhibitor drug zanamivir. "
3.	Influenza in Birds (Avian Flu) 02/01/2010 - "Antiviral testing of compounds 1-11 against KBNP-0028 (H9N2) avian influenza virus showed that platyphyllone (10) was strongly active, and platyphyllonol-5-xylopyranoside (9) was moderately active against KBNP-0028 as compared with the positive control, zanamivir, respectively." 10/01/2006 - "Sixteen novel 4-triazole-modified zanamivir (1) analogues were synthesized using the click reactions, and their inhibitory activities against avian influenza virus (AIV, H5N1) were determined. " 04/01/2001 - "Thus, zanamivir is efficacious in treating avian influenza viruses that can be transmitted to mammals." 08/01/2012 - "Further preliminary anti-avian influenza virus (AIV, H5N1) activities against infected MDCK cells were evaluated, and D5 exerts ∼58% protective against AIV infection, which was comparable to zanamivir (∼67%). " 03/01/2010 - "N-acetyl-D-neuraminic acid (Neu5Ac) is a precursor for producing many pharmaceutical drugs such as zanamivir which have been used in clinical trials to treat and prevent the infection with influenza virus, such as the avian influenza virus H5N1 and the current 2009 H1N1. "
4.	Pneumonia (Pneumonitis) 01/01/2014 - "Zanamivir did not reduce the risk of self reported investigator mediated pneumonia (risk difference 0.17%, -0.73% to 0.70%) or radiologically confirmed pneumonia (-0.06%, -6.56% to 2.11%) in adults. " 01/01/2014 - "There was no significant effect of zanamivir on either self reported or radiologically confirmed pneumonia. " 05/01/2010 - "Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus." 09/19/2009 - "H1N1 pneumonitis treated with intravenous zanamivir." 01/01/2010 - "Prone Positioning and Intravenous Zanamivir may Represent Effective Alternatives for Patients with Severe ARDS Virus A (H1N1) Related Pneumonia in Hospitals with no Access to ECMO."
5.	Otitis Media 01/01/2007 - "Only oseltamivir produced a significant reduction in the complications of influenza (particularly otitis media), although there was a trend to benefit for zanamivir. " 01/01/2003 - "Only oseltamivir produced a significant reduction in the complications of influenza (particularly otitis media), although there was a trend to benefit for zanamivir. " 12/08/2000 - "However, intranasal zanamivir and oral oseltamivir significantly reduced MEP abnormalities during experimental influenza in adults, and oseltamivir treatment appears to reduce the likelihood of otitis media in children with acute influenza. "

Related Drugs and Biologics

1.	Oseltamivir (Tamiflu)
2.	Neuraminidase (Sialidase)
3.	Zanamivir (Relenza)
4.	Amantadine (Aman)
5.	Rimantadine
6.	Antiviral Agents (Antivirals)
7.	R 125489
8.	peramivir
9.	CS 8958
10.	15- methyl- 8- aza- 16- oxagona- 1,3,5(10),13- tetraen- 17- one (MAOTO)

Related Therapies and Procedures

1.	Chemoprevention
2.	Home Nursing (Nursing, Home)
3.	Intranasal Administration
4.	Inhalation Administration
5.	Long-Term Care